Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
Authors
Keywords
-
Journal
Biomolecules
Volume 11, Issue 4, Pages 492
Publisher
MDPI AG
Online
2021-03-26
DOI
10.3390/biom11040492
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Systematic Review and Network Meta-Analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-Resistant Prostate Cancer
- (2020) Amanda E. Hird et al. Clinical Genitourinary Cancer
- Treatment of non-mestastatic castration resistant prostate cancer in 2020: What is the best?
- (2020) Isabel Heidegger et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
- (2020) Steven Kregel et al. NEOPLASIA
- Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
- (2020) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
- (2020) Eric Jay Small et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
- (2020) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Options for First-Line Metastatic Castration-Resistant Prostate Cancer: Suggestions for Clinical Practise in the CHAARTED and LATITUDE Era
- (2019) Marcello Tucci et al. CANCER TREATMENT REVIEWS
- Cabazitaxel inhibits prostate cancer cell growth by inhibition of androgen receptor and heat shock protein expression
- (2019) Anja-Martina Rottach et al. WORLD JOURNAL OF UROLOGY
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer
- (2019) Neal D. Shore et al. CLINICAL THERAPEUTICS
- The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer (nmCRPC) patients from the MDV claims database in Japan
- (2019) Asuka Mori et al. CURRENT MEDICAL RESEARCH AND OPINION
- Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis
- (2019) Wei Lu et al. DEVELOPMENTAL CELL
- Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer
- (2019) Giovanni L. Beretta et al. Frontiers in Chemistry
- Targeted protein degradation: elements of PROTAC design
- (2019) Stacey-Lynn Paiva et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate Cancer
- (2019) Aradhana Rani et al. AMERICAN JOURNAL OF PATHOLOGY
- Relationship Between Metastasis-Free Survival and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
- (2019) Matthew R. Smith et al. Clinical Genitourinary Cancer
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1
- (2018) Pedro Nicolau-Neto et al. Genes
- Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9 led to increase docetaxel sensitivity via suppressing the p21 expression
- (2018) Jie Luo et al. CANCER LETTERS
- ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).
- (2018) Geraldine Martineau et al. JOURNAL OF CLINICAL ONCOLOGY
- A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer
- (2018) Milly J. McAllister et al. Translational Research
- Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
- (2017) Ronghao Wang et al. EUROPEAN UROLOGY
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- Integrative clinical genomics of metastatic cancer
- (2017) Dan R. Robinson et al. NATURE
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
- (2017) Semini Sumanasuriya et al. Cold Spring Harbor Perspectives in Medicine
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
- (2016) Jun Luo ASIAN JOURNAL OF ANDROLOGY
- ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L
- (2016) Ronghao Wang et al. CANCER LETTERS
- A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer
- (2016) Xichun Liu et al. JOURNAL OF UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- (2016) Akash Kumar et al. NATURE MEDICINE
- Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging
- (2015) Jeffrey L. Gustafson et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Metastatic castration-resistant prostate cancer: time for innovation
- (2015) Marcello Tucci et al. Future Oncology
- AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies
- (2015) A. Omlin et al. INVESTIGATIONAL NEW DRUGS
- Sequencing of agents in castration-resistant prostate cancer
- (2015) David Lorente et al. LANCET ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- AR Variant ARv567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer
- (2015) Gang Liu et al. NEOPLASIA
- Stromal Androgen Receptor in Prostate Development and Cancer
- (2014) Mandeep Singh et al. AMERICAN JOURNAL OF PATHOLOGY
- The Role of M1 and M2 Macrophages in Prostate Cancer in relation to Extracapsular Tumor Extension and Biochemical Recurrence after Radical Prostatectomy
- (2014) M. Lanciotti et al. Biomed Research International
- Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
- (2013) Lucas J. Brand et al. CURRENT DRUG TARGETS
- Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
- (2013) Mark Sanford DRUGS
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- The Androgen Receptor in Health and Disease
- (2012) Takahiro Matsumoto et al. Annual Review of Physiology
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- Reciprocal Metabolic Reprogramming through Lactate Shuttle Coordinately Influences Tumor-Stroma Interplay
- (2012) T. Fiaschi et al. CANCER RESEARCH
- The androgen receptor gene mutations database: 2012 update
- (2012) Bruce Gottlieb et al. HUMAN MUTATION
- Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal
- (2012) Siu Chiu Chan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Associated Fibroblasts Exploit Reactive Oxygen Species Through a Proinflammatory Signature Leading to Epithelial Mesenchymal Transition and Stemness
- (2011) Elisa Giannoni et al. ANTIOXIDANTS & REDOX SIGNALING
- Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer
- (2011) Robert H. Bradbury et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Androgen receptor and its splice variants in prostate cancer
- (2011) Simon Haile et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
- (2011) G. Attard et al. CLINICAL CANCER RESEARCH
- Alternatively spliced androgen receptor variants
- (2011) Scott M Dehm et al. ENDOCRINE-RELATED CANCER
- The cancer stem cell niche-there goes the neighborhood?
- (2011) Stephanie M. Cabarcas et al. INTERNATIONAL JOURNAL OF CANCER
- Effects of Androgen Receptor and Androgen on Gene Expression in Prostate Stromal Fibroblasts and Paracrine Signaling to Prostate Cancer Cells
- (2011) Matthew J. Tanner et al. PLoS One
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives
- (2011) Nagalakshmi Nadiminty et al. WORLD JOURNAL OF UROLOGY
- Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer
- (2010) Norio Nonomura et al. BJU INTERNATIONAL
- Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients
- (2010) S Crnalic et al. ENDOCRINE-RELATED CANCER
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy
- (2009) M. P. Steinkamp et al. CANCER RESEARCH
- Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
- (2009) Philippe O. Gannon et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Prostatic Tumor Stroma: A Key Player in Cancer Progression
- (2008) R. Taylor et al. CURRENT CANCER DRUG TARGETS
- Pleiotropic functional properties of androgen receptor mutants in prostate cancer
- (2008) Jean-Pierre Bergerat et al. HUMAN MUTATION
- Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion
- (2008) Yirong Li et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now